Fertility preservation for adolescent and young adult cancer patients in Japan

키워드

참고문헌 (47)

1. Cancer epidemiology in older adolescents and young adults 15 to 29 years of age: including SEER incidence and survival: 1975-2000, "Bleyer A", U.S. Department of Health and Human Services, National Institutes of Health, ~ (2006)
2. Coccia PF, "Adolescent and young adult oncology. Clinical practice guidelines in oncology", J Natl Compr Canc Netw, 10, pp.1112~1150 (2012)[DOI]
3. "SEER cancer statistics review (CSR) 1975-2013" (2016)[URL]
4. "Cancer Statistics in Japan 2015" (2015)[URL]
5. Lee SJ, "American Society of Clinical Oncology recommendations on fertility preservation in cancer patients", J Clin Oncol, 24, pp.2917~2931 (2006)[DOI]
6. Loren AW, "Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update", J Clin Oncol, 31, pp.2500~2510 (2013)[DOI]
7. Japan Society of Clinical Oncology, "JSCO clinical practice guidelines 2017 for fertility preservation in childhood, adolescent and young adult cancer patients", Japan Society of Clinical Oncology, ~ (2017)
8. Practice Committees of American Society for Reproductive Medicine, "Mature oocyte cryopreservation: a guideline", Fertil Steril, 99, pp.37~43 (2013)[DOI]
9. Cakmak H, "Effective method for emergency fertility preservation: randomstart controlled ovarian stimulation", Fertil Steril, 100, pp.1673~1680 (2013)[DOI]
10. Reddy J, "Triggering final oocyte maturation with gonadotropin-releasing hormone agonist (GnRHa) versus human chorionic gonadotropin (hCG) in breast cancer patients undergoing fertility preservation: an extended experience", J Assist Reprod Genet, 31, pp.927~932 (2014)[DOI]
11. Oktay K, "Fertility preservation success subsequent to concurrent aromatase inhibitor treatment and ovarian stimulation in women with breast cancer", J Clin Oncol, 33, pp.2424~2429 (2015)[DOI]
12. Japan Society of Obstetrics, "Views on unfertilized oocytes, embryos and ovarian tissues freezing and preservation by medical adaptation", Acta Obstet Gynaecol Jpn, 68, pp.1470~1474 (2016)
13. Oktay K, "Ovarian function after transplantation of frozen, banked autologous ovarian tissue", N Engl J Med, 342, pp.1919~ (2000)
14. Donnez J, "Livebirth after orthotopic transplantation of cryopreserved ovarian tissue", Lancet, 364, pp.1405~1410 (2004)[DOI]
15. von Wolff M, "Fertility-preservation counselling and treatment for medical reasons: data from a multinational network of over 5000 women", Reprod Biomed Online, 31, pp.605~612 (2015)[DOI]
16. Practice Committee of American Society for Reproductive Medicine, "Ovarian tissue cryopreservation: a committee opinion", Fertil Steril, 101, pp.1237~1243 (2014)[DOI]
17. Jensen AK, "86 successful births and 9 ongoing pregnancies worldwide in women transplanted with frozenthawed ovarian tissue: focus on birth and perinatal outcome in 40 of these children", J Assist Reprod Genet, 34, pp.325~336 (2017)[DOI]
18. Suzuki N, "Ovarian tissue cryopreservation using vitrification and", or in vitro activated technology, 2015, pp.30, 2461~2462
19. Suzuki N, "Successful fertility preservation following ovarian tissue vitrification in patients with primary ovarian insufficiency", Hum Reprod, 30, pp.608~615 (2015)[DOI]
20. Kawamura K, "Hippo signaling disruption and Akt stimulation of ovarian follicles for infertility treatment", Proc Natl Acad Sci USA, 110, pp.17474~17479 (2013)[DOI]
21. Shi Q, "Vitrification versus slow freezing for human ovarian tissue cryopreservation: a systematic review and meta-anlaysis", Sci Rep, 7, pp.8538~ (2017)[DOI]
22. Kawahara T, "Vitrification versus slow freezing of human ovarian tissue: a comparison of follicle survival and DNA damage", Fertil Steril, 108, pp.e56~e57 (2017)
23. Sugishita Y, "Comparison of open and closed devices in human ovarian tissue vitrification", Fertil Steril, 108, pp.e172~e173 (2017)
24. Takae S, "Accuracy and safety verification of ovarian reserve assessment technique for ovarian tissue transplantation using optical coherence tomography in mice ovary", Sci Rep, 7, pp.43550~ (2017)[DOI]
25. Dolmans MM, "Reimplantation of cryopreserved ovarian tissue from patients with acute lymphoblastic leukemia is potentially unsafe", Blood, 116, pp.2908~2914 (2010)[DOI]
26. Greve T, "Cryopreserved ovarian cortex from patients with leukemia in complete remission contains no apparent viable malignant cells", Blood, 120, pp.4311~4316 (2012)[DOI]
27. Dolmans MM, "Risk of transferring malignant cells with transplanted frozen-thawed ovarian tissue", Fertil Steril, 99, pp.1514~1522 (2013)[DOI]
28. Hoekman EJ, "Searching for metastases in ovarian tissue before autotransplantation: a tailor-made approach", Fertil Steril, 103, pp.469~477 (2015)[DOI]
29. Donnez J, "Fertility preservation for age-related fertility decline", Lancet, 385, pp.506~507 (2015)
30. Wallace WH, "Fertility preservation for girls and young women with cancer: population-based validation of criteria for ovarian tissue cryopreservation", Lancet Oncol, 15, pp.1129~1136 (2014)[DOI]
31. Sugishita Y, "Ovarian tissue vitrification: ovarian tissue cryopreservation and transplantation", Ishiyakushuppan, 7, pp.46~59 (2017)
32. Takae S, "The role of menstrual cycle phase and AMH levels in breast cancer patients whose ovarian tissue was cryopreserved for oncofertility treatment", J Assist Reprod Genet, 32, pp.305~312 (2015)[DOI]
33. Xiao S, "Size-specific follicle selection improves mouse oocyte reproductive outcomes", Reproduction, 150, pp.183~192 (2015)[DOI]
34. Ataya K, "Luteinizing hormone-releasing hormone agonist inhibits cyclophosphamide-induced ovarian follicular depletion in rhesus monkeys", Biol Reprod, 52, pp.365~372 (1995)[DOI]
35. Del Mastro L, "Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trial", JAMA, 306, pp.269~276 (2011)
36. Lambertini M, "Ovarian suppression with triptorelin during adjuvant breast cancer chemotherapy and long-term ovarian function, pregnancies, and disease-free survival, a randomized clinical trial", JAMA, 314, pp.2632~2640 (2015)[DOI]
37. Munster PN, "Randomized trial using gonadotropin-releasing hormone agonist triptorelin for the preservation of ovarian function during (neo)adjuvant chemotherapy for breast cancer", J Clin Oncol, 30, pp.533~538 (2012)[DOI]
38. Gerber B, "Effect of luteinizing hormonereleasing hormone agonist on ovarian function after modern adjuvant breast cancer chemotherapy: the GBG 37 ZORO study", J Clin Oncol, 29, pp.2334~2341 (2011)[DOI]
39. Moore HC, "Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy", N Engl J Med, 372, pp.923~932 (2015)[DOI]
40. Demeestere I, "No evidence for the benefit of gonadotropin-releasing hormone agonist in preserving ovarian function and fertility in lymphoma survivors treated with chemotherapy: final long-term report of a prospective randomized trial", J Clin Oncol, 34, pp.2568~2574 (2016)[DOI]
41. Munhoz RR, "Gonadotropin-releasing hormone agonists for ovarian function preservation in premenopausal women undergoing chemotherapy for early-stage breast cancer: a systematic review and meta-analysis", JAMA Oncol, 2, pp.65~73 (2016)[DOI]
42. Oktay K, "Failure of ovarian suppression with gonadotropin-releasing hormone analogs to preserve fertility: an assessment based on the quality of evidence", JAMA Oncol, 2, pp.74~75 (2016)[DOI]
43. Coccia PF, "Adolescent and young adult oncology, version 2.2014", J Natl Compr Canc Netw, 12, pp.21~32 (2014)[DOI]
44. Moss JL, "Male adolescent fertility preservation", Fertil Steril, 105, pp.267~273 (2016)[DOI]
45. Gupta AA, "Testicular biopsy for fertility preservation in prepubertal boys with cancer. Identifying preferences for procedure and reactions to disclosure practices", J Urol, 196, pp.219~224 (2016)[DOI]
46. Long CJ, "Fertility preservation in children and adolescents with cancer", Urology, 91, pp.190~196 (2016)[DOI]
47. Woodruff TK, "The emergence of a new interdiscipline: oncofertility", Cancer Treat Res, 138, pp.3~11 (2007)

관련 논문AI추천